The POPular TAVI trial is an open label randomized study designed to evaluate oral anticoagulation (OAC) alone compared with OAC plus clopidogrel for 3 months in patients undergoing transcatheter aortic valve replacement (TAVR) with a long-term indication for oral anticoagulation. Those who had undergone percutaneous revascularization...

Luigi Biasco provides his take on a sub-analysis of the Early TAVR trial about the early and delayed aortic valve replacement implant patients presented by Philippe Genereux at ACC.25 in Chicago.

Luigi Biasco provides his take on the results of the EARLY TAVR trial, presented by Philippe Genereux at TCT 2024 in Washington.

Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.